In this phase II study, patients with solid tumors will receive treatment with hiltonol and autologous dendritic cells.

In this phase II study, patients with solid tumors will receive treatment with intratumoral hiltonol and two cycles of autologous dendritic cells loaded with autologous tumor and administered subcutaneously. A new cohort will explore the role of radiation therapy, looking for an abscopal effect.

Inclusion Criteria:

• Confirmed diagnosis of advanced solid tumors
• Measurable disease
• Performance status 0, 1 or 2.
• Adequate renal, hepatic and bone marrow function
• Availability of tumor tissue, for maturing dendritic cells

Exclusion Criteria:

• Clinically relevant diseases or infections.
• concurrent participation in other clinical trial or administration or other antitumoral treatment
• Concurrent cancer, with the exceptions allowed by the PI.
• Pregnant or breast feeding women
• immunosuppressant treatment
• known uncontrolled central nervous system metastasis